BG
FMTX

Bollard Group’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Bollard Group’s Portfolio FMTX Stock Details FMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-158,200
Closed -$1.47M – 433
2022
Q1 		$1.47M Buy
+158,200
New +$1.68M 0.05% 127

Other funds holding FMTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
EPL
EDBI Pte Ltd Singapore $94.4M AUM 32.71% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bollard Group's FMTX Position: Q2 2022 in Review

Bollard Group sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q2 2022, closing a stake of 158,200 shares — an estimated $1.47M sold.

Bollard Group first reported a position in FMTX in Q1 2022 and held it in 1 quarter. The position peaked at $1.47M in Q1 2022. 105 funds tracked by Wall St. Rank hold FMTX as of Q2 2022.

  • Bollard Group reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bollard Group sold 158,200 Forma Therapeutics Holdings, Inc. Common Stock shares in Q2 2022, an estimated $1.47M.
  • Bollard Group first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Bollard Group's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $1.47M in Q1 2022.
  • 105 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.